What is LMWH?
Low-molecular-weight heparin (LMWH) is a class of anticoagulant medications derived from unfractionated heparin through chemical or enzymatic depolymerization, producing fragments approximately one-third the size of standard heparin with molecular weights ranging from 4,000-6,000 Daltons. 1, 2
Chemical Structure and Production
LMWHs are created by breaking down standard heparin using different methods:
- Chemical depolymerization (nitrous acid, alkaline treatment, benzylation)
- Enzymatic depolymerization (using heparinase)
Each manufacturing method produces a distinct LMWH product with unique pharmacologic properties 2, 3. Clinically available LMWHs include enoxaparin, dalteparin, tinzaparin, nadroparin, and others—these are NOT interchangeable because they differ in molecular weight distribution, anti-Xa to anti-IIa ratios (ranging from 1.9 to 3.8), and pharmacokinetic profiles 1, 2.
Mechanism of Action
LMWHs work by activating antithrombin through a specific pentasaccharide sequence. The key difference from unfractionated heparin:
- Chains with ≥18 saccharide units (25-50% of LMWH molecules) can inactivate both thrombin (factor IIa) and factor Xa
- Chains with <18 saccharide units retain anti-factor Xa activity but lose anti-thrombin activity
- Result: LMWHs have enhanced anti-Xa activity relative to anti-IIa activity compared to unfractionated heparin 4, 1
Key Pharmacologic Advantages
LMWHs offer superior pharmacokinetics compared to unfractionated heparin due to reduced binding to plasma proteins, blood cells, and endothelial cells 1, 2:
- Higher bioavailability (≥90% subcutaneous absorption vs. variable with UFH) 5
- Longer half-life allowing once or twice-daily dosing
- Predictable dose-response relationship enabling weight-based dosing without routine monitoring
- Dose-independent clearance with more consistent anticoagulation 1
Clinical Advantages
Practical benefits that make LMWHs preferable to unfractionated heparin in most situations 4:
- Subcutaneous administration (no IV access required)
- No need for aPTT monitoring in most patients
- Lower rates of heparin-induced thrombocytopenia 4
- Reduced platelet factor 4 sensitivity 4
- Less osteoporosis with long-term use 2
- Facilitates outpatient treatment 6
Important Caveats
Renal clearance: LMWHs are primarily cleared by the kidneys, requiring dose adjustment or avoidance in severe renal insufficiency (creatinine clearance <30 mL/min). Enoxaparin has specific dosing recommendations for this population (30 mg daily for prophylaxis, 1 mg/kg every 24 hours for treatment) 6.
No complete reversal agent: Unlike unfractionated heparin (which is reversed with protamine sulfate), LMWHs lack a complete antidote. Protamine can partially reverse LMWH but only neutralizes about 60% of anti-Xa activity 1.
Not interchangeable: Each LMWH is a distinct drug product—clinical data for one cannot be extrapolated to another 2, 3, 5.